Entry Point Capital, LLC Stoke Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 31,968 shares of STOK stock, worth $329,909. This represents 0.16% of its overall portfolio holdings.
Number of Shares
31,968Holding current value
$329,909% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
131Shares Held
55.8MCall Options Held
9.3KPut Options Held
35.2K-
Skorpios Trust6.91MShares$71.3 Million99.8% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$55.8 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.19MShares$53.5 Million22.82% of portfolio
-
Redmile Group, LLC San Francisco, CA4.71MShares$48.6 Million3.79% of portfolio
-
Rtw Investments, LP New York, NY4.65MShares$48 Million0.91% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $407M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...